Durata Sets Sights On Commercialization As Dalbavancin Nears Filing

After completing an initial public offering in July, announcing plans to relocate its corporate headquarters to Chicago in November and releasing positive Phase III data on its lead drug, the antibiotic dalbavancin, Dec. 11, Durata Therapeutics is laying the groundwork to transition to a commercial drug company.